Roche dismisses Novo Nordisk as potential threat on lucrative hemophilia market

Novo Nordisk's future hemophilia drugs face a difficult challenge in reconquering the profitable hemophilia drug market, says CEO at Roche, which is currently shepherding a big part of the loyal hemophiliac flock.
Photo: Roche / PR
Photo: Roche / PR

The pharmaceutical giant Roche has in a short time seized large portions of the world's hemophiliac market, a lead that the Swiss company and competitor of Novo Nordisk expects to maintain.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading